Management EfficiencyThe company has return on total asset (ROA) of 13.63 % which means that it generated profit of $13.63 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 27.22 % meaning that it generated $27.22 on every $100 dollars invested by stockholders.
Entity SummarySwedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Market in USA.Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Tomtebodav?gen 23A and employs 842 people.
Swedish Orphan Biovi Leadership Team
Stock Performance Indicators